跳至主要内容
临床试验/NCT06911086
NCT06911086尚未招募2 期

SH-LPS System in Preoperative Planning for Liver Resection: a Randomized Controlled Trial

Zhejiang Cancer Hospital0 个研究点目标入组 100 人开始时间: 2025年4月15日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
尚未招募
入组人数
100
主要终点
Opertation duration

研究概览

简要总结

Effective preoperative planning and real-time intraoperative guidance are crucial for performing accurate liver resections. To address this need, the researchers have designed advanced 3D-printed liver models using a self-healing elastomer, created through the copolymerization of 4-acryloylmorpholine (ACMO) and methoxy poly(ethylene glycol) acrylate (mPEGA). These models demonstrate outstanding healing properties, swiftly restoring their structure within minutes at room temperature, and quickly recovering after incisions.

In previous studies, Professor Yuhua Zhang, the project applicant, collaborated with a team from Zhejiang University to develop a 3D-printed liver model that is self-healing and reusable for repeated cutting. They preliminarily explored the feasibility of applying this model for preoperative planning and surgical training for liver surgeries. The results were published in Nature Communications (Lu et al., Nat Commun. Dec 19;14(1):8447). Building on this, the applicant intends to establish a personalized liver surgery planning system (Personalized Liver Surgery Planning System Based on High-Fidelity 3D Printed Self-Healing Liver Models, SH-LPS), which will assess, through a randomized controlled trial, the value of SH-LPS in improving liver surgery efficiency and safety.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •18-80 years old;
  • •Patients with a resectable tumor in the liver;
  • •Eastern Cooperative Oncology Group Performance status score: 0;
  • •Child-Pugh classification: A;
  • •The Laboratory test results meet the following criteria and patients can tolerate surgery: Haemoglobin≥90g/L, Neutrophil count≥1.5×10⁹/L, Platelet count≥100×10⁹/L, Aspartate or alanine aminotransferase≤5 upper limits of normal(ULN), alkaline phosphatase≤2.5 ULN, Serum albumin≥30g/L, serum creatinine<1.5 ULN, International normalized ratios(INR)≤2 or rothrombin time(PT)exceed ULN≤6s, Creatinine clearance≥60 mL/min.

排除标准

  • •Patients with extra-hepatic metastasis;
  • •Anti-cancer therapy or surgery such as radiotherapy, radiofrequency ablation in 28 days prior to the surgery;
  • •Clinically significant bleeding or bleeding tendencies within 3 months prior to enrollment or on thrombolytic or anticoagulant therapy;
  • •Severe lung disease (eg, acute lung disease, pulmonary fibrosis that affects lung function, interstitial lung disease), uncontrolled diabetes mellitus (fasting blood glucose ≥10 mmol/L);
  • •There are other unsuitable candidates for clinical trials, such as mental illness or alcohol dependence.

研究组 & 干预措施

3D group

Experimental

A three-dimensional digital model is constructed based on the patient's CT/MRI data and a physical model is printed. Using the model's self-healing property after cutting, multiple simulated surgeries are performed to help plan the optimal surgical approach. The best surgical path derived from the model is combined with traditional CT/MRI data to determine the final surgical path, and the surgery is then performed according to this finalized path.

干预措施: 3D printed models (Device)

CT/MRI group

Sham Comparator

The surgical approach is planned based on traditional two-dimensional CT/MRI images, and the surgery is performed according to this planned path.

干预措施: CT or MRI image (Other)

结局指标

主要结局

Opertation duration

时间窗: Until the end of the surgey

The duration from the start to the end of the surgery.

Blood loss

时间窗: Until the end of the surgey

Blood loss during the operation

次要结局

  • R0 resection rate(Until the day the official pathology report comes out, an average of two weeks)
  • Surgical complications(Until three months after the surgery)
  • Postoperative hospital stay.(Until the day the patient is discharged, an average of one week.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yuhua Zhang, MD

Principal Investigator, Director of Hepatopancreatobiliary Surgery

Zhejiang Cancer Hospital

相似试验